Printer Friendly

PROCYTE LICENSES WOUND HEALING TECHNOLOGY TO PARTNER IN JAPAN

 KIRKLAND, Wash., Dec. 1 /PRNewswire/ -- ProCyte Corp. (NASDAQ-NMS: PRCY) announced today that it has formed a strategic alliance with Kissei Pharmaceutical Co., Ltd., Matsumoto-City, Japan, for development and marketing in Asia of ProCyte's topical peptide-copper wound healing technology known as the Iamin(R) compound.
 Under the terms of the agreement, Kissei will have exclusive license rights for ProCyte's Iamin compound for wound healing applications, which include treatment of dermal wounds such as diabetic, decubitus and venous stasis ulcers, surgical wounds and burns. Kissei will be responsible for clinical testing and registration of the technology in Japan and certain Asian countries.
 ProCyte will supply preclinical and clinical trial quantities of the drug substance. Research and development will be conducted by both companies and they will work together to expand the clinical testing of the Iamin compound, which is currently in Phase III human studies in the United States for treatment of diabetic neuropathic plantar ulcers.
 Kissei will make a $4 million equity investment in ProCyte's common stock, and will pay R&D fees, milestone payments and royalties on products sold in the territory in exchange for rights to the Iamin compound. Additional terms were not disclosed.
 "We are pleased to announce this strategic partnership with Kissei," said Joseph Ashley, ProCyte's president and chief executive officer. "We believe that Kissei's reputation for innovative pharmaceutical product development, and its knowledge of the Asian regulatory and market requirements, will complement our commitment to introduce our technology and improve health care worldwide."
 In a statement issued by Kissei, the company said that the problems experienced in an aging population in Japan has led to an increase in chronic dermal wounds, such as diabetic and decubitus ulcers, which are also known as bedsores. This has drawn considerable medical attention in Japan and is considered an important medical problem.
 Kissei develops and markets dermatological products, and its anti-allergy drug, Rizaben(R), has been widely used for atopic dermatitis. In October, the drug was approved for keloid and hypertrophic scar treatments. Kissei has made a strategic commitment to build its product pipeline in the dermatology field.
 ProCyte is a pharmaceutical company that is developing a proprietary family of copper therapeutics for both topical and systemic administration in tissue repair and other indications.
 -0- 12/1/93
 /CONTACT: Karen L. Hedine, vice president, or Joseph Ashley, president and chief executive officer of ProCyte, 206-820-4548/
 (PRCY)


CO: ProCyte Corp.; Kissei Pharmaceutical Co., Ltd. ST: Washington IN: MTC SU: LIC

RB-IC -- SE004 -- 9063 12/01/93 08:31 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 1, 1993
Words:418
Previous Article:INNOVET BIOTECH PRODUCT MEETS USDA PERFORMANCE STANDARDS FOR LICENSING
Next Article:MAKING INFORMED WEIGHT-MANAGEMENT DECISIONS JUST GOT EASIER FOR CONSUMERS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters